FY18 has started well and we are trading in line with expectations, with pleasing year-on-year growth in solutions across both ES and SMB. • Over 2017 and 2018 we are making investments to maintain the strong growth of recent years. As a result in FY18 we expect revenue to grow in line with last year but EBITDA and profit will temporarily grow at a slower rate than recent years. • Having absorbed these investments in FY18, EBITDA and profit growth will accelerate in FY19.
- Forums
- ASX - By Stock
- Share Price weakness
FY18 has started well and we are trading in line with...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ARQ (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online